Evidence mapPaperPMID 40128666Full record

SynthesisBMC cardiovascular disorders2025

The role of bariatric surgery in hypertension control: a systematic review and meta-analysis with extended benefits on metabolic factors.

Parham Dastjerdi, Seyed Morteza Pourfaraji, Hedieh Shayesteh, Milad Maghsoudi, Sahar Saeidi, Delaram Narimani Davani, Mohammad Mahdi Masouri, Peyvand Parhizkar Roudsari, Fatemeh Ojaghi Shirmard, Pouya Ebrahimi and 3 more

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Prevalence and risk factors of acute kidney injury in adults with obesity undergoing bariatric surgery: a systematic review and meta-analysis.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Foods (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Parham DastjerdiTehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0009-0007-3386-7697
Seyed Morteza PourfarajiTehran University of Medical Sciences, Tehran, Iran.ORCID 0009-0003-7712-9427
Hedieh ShayestehTehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0009-0002-8450-4662
Milad MaghsoudiChild Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID 0000-0001-7485-4437
Sahar SaeidiCardiac Primary Prevention Research Center, Cardiovascular Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-1973-6961
Delaram Narimani DavaniHeart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Science, Isfahan, Iran.ORCID 0009-0007-3881-0040
Mohammad Mahdi MasouriShahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0009-0009-4243-5698
Peyvand Parhizkar RoudsariThe Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-3521-0959
Fatemeh Ojaghi ShirmardTehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0009-0009-6675-6998
Pouya EbrahimiTehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0009-0005-3694-6863
Mashood Ahmad FarooqiDepartment of Internal Medicine, Central Michigan University College of Medicine, Saginaw, MI, 48602, USA.ORCID 0009-0002-5033-0895
Kaveh HosseiniTehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-5676-3099
Hamidreza SoleimaniTehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Hamid.R.Soleimani90@gmail.com.ORCID 0000-0003-2802-4613

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBy 2025, global obesity rates are projected to reach 16% in men and 21% in women, imposing a significant public health burden. Obesity is a major contributor to hypertension (HTN), exacerbating cardiovascular risks. This review and meta-analysis evaluated the effectiveness of non-surgical treatments versus bariatric surgery in managing hypertension among obese individuals.

methodsWe searched PubMed, Scopus, Embase, and Cochrane databases up to May 2024. Randomized controlled trials (RCTs) comparing bariatric surgery (e.g., Roux-en-Y Gastric Bypass (RYGB), Sleeve gastrectomy (SG), Laparoscopic adjustable gastric banding (LAGB), Duodenal-jejunal bypass liner/Biliopancreatic diversion (DJBL/BPD)) with non-surgical interventions (e.g., lifestyle modifications, medications) in hypertensive obese patients were included. Primary outcomes were changes in systolic and diastolic blood pressure. Secondary outcomes included changes in fasting blood sugar (FBS), HbA1c, and lipid profiles. Data were synthesized using a random-effects model, with heterogeneity and publication bias assessed.

resultsFrom 7,187 records, 29 studies involving 2,548 patients met the inclusion criteria. Bariatric surgery resulted in greater reductions in systolic (MD: -4.506 mmHg; 95% CI: -6.999 to -2.013) and diastolic (MD: -3.040 mmHg; 95% CI: -4.765 to -1.314) blood pressure compared to non-surgical interventions. Roux-en-Y gastric bypass had the most significant impact. Bariatric surgery also led to substantial reductions in FBS (MD: -30.444 mg/dl; 95% CI: -41.288 to -19.601), HbA1c (MD: -1.108%; 95% CI: -1.414 to -0.802), and triglycerides (MD: -39.746 mg/dl; 95% CI: -54.458 to -25.034), and increased HDL levels (MD: 7.387 mg/dl; 95% CI: 5.056 to 9.719). The quality of evidence was high for most outcomes, supporting these findings.

conclusionBariatric surgery is superior to non-surgical treatments in managing obesity-related hypertension and metabolic disorders. Reductions in blood pressure, glycemic indexes, and lipid profiles highlight bariatric surgery's critical role in improving cardiovascular health and metabolic outcomes in obese hypertensive patients.

Indexed as

Bariatric SurgeryBlood PressureHypertensionLipidsObesityWeight LossAdultAntihypertensive AgentsBiomarkersBlood GlucoseFemaleGlycated HemoglobinHumansMaleMiddle AgedTreatment OutcomeAntihypertensive AgentsBiomarkersBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanLipidsBariatric surgeryBlood pressure reductionHypertensionObesity

Identifiers

PMID40128666
PMCPMC11931862

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.